Ossiform
Develops and manufactures patient-specific, resorbable bone implants using a proprietary 3D printing technology that are replaced by the patient's own bone over time.
- CEO / Founder
- Thea Wulff Olesen
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $28.0M
- Latest Round
- Venture Round
- Key Investors
- West Hill Capital, Asimov Ventures, Vækstfonden (The Danish Growth Fund), PreSeed Ventures
Technology & Products
Key Products
["P3D Scaffolds (for research use)","Patient-specific bone implants (in development for clinical use)","Ossi Ink (in partnership with CELLINK)"]
Technological Advantage
The ability to create customized, patient-specific implants on-demand provides a significant advantage over standard-sized metal or allograft implants, leading to better surgical outcomes and reduced surgery time. The technology is protected by a strong IP portfolio.
Differentiation
Value Proposition
Providing patient-matched, natural, and fully resorbable bone implants that improve surgical outcomes, reduce complications, and enhance bone regeneration compared to traditional implants.
How They Differentiate
Ossiform differentiates by offering fully resorbable, patient-specific implants made from a proprietary bioceramic that mimics natural bone, whereas many competitors focus on permanent metal (titanium) implants or allografts. Their focus on complete regeneration sets them apart.
Market & Competition
Target Customers
Hospitals, surgeons (orthopedic, maxillofacial, craniofacial), and medical research institutions.
Industry Verticals
["Medical","Healthcare","Biotechnology"]
Competitors
Theradaptive, Ossio, MiMedx Group
Growth & Milestones
Growth Metrics
Expanding its team, securing international partnerships, and moving towards FDA clearance for its clinical products. The company has successfully launched its research-use products (P3D Scaffolds) globally.
Major Milestones
["Founded in 2017 as a spinout from the University of Southern Denmark.","Rebranded from Particle3D to Ossiform in early 2022.","Secured multiple rounds of funding, including a significant round in October 2022.","Established key strategic partnerships with CELLINK, Asimov Ventures, and CAM Bioceramics.","Launched P3D Scaffolds for the global research market and developed Ossi Ink with CELLINK."]
Notable Customers
Research institutions and universities worldwide using P3D Scaffolds. Clinical customers are anticipated upon regulatory approval.